Advanced search
1 file | 210.82 KB

Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour

Author
Organization
Abstract
Positron emission tomography (PET) using 6-[(18)F]fluoro-L-dihydroxyphenylalanine ((18)F-dopa) has an excellent sensitivity to detect carcinoid tumour lesions. (18)F-dopa tumour uptake and the levels of biochemical tumour markers are mediated by tumour endocrine metabolic activity. We evaluated whether total (18)F-dopa tumour uptake on PET, defined as whole-body metabolic tumour burden (WBMTB), reflects tumour load per patient, as measured with tumour markers. Seventy-seven consecutive carcinoid patients who underwent an (18)F-dopa PET scan in two previously published studies were analysed. For all tumour lesions mean standardised uptake values (SUVs) at 40% of the maximal SUV and tumour volume on (18)F-dopa PET were determined and multiplied to calculate a metabolic burden per lesion. WBMTB was the sum of the metabolic burden of all individual lesions per patient. The 24-h urinary serotonin, urine and plasma 5-hydroxindoleacetic acid (5-HIAA), catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A served as tumour markers. All but 1 were evaluable for WBMTB; 74 patients had metastatic disease. (18)F-dopa PET detected 979 lesions. SUV(max) on (18)F-dopa PET varied up to 29-fold between individual lesions within the same patients. WBMTB correlated with urinary serotonin (r = 0.51) and urinary and plasma 5-HIAA (r = 0.78 and 0.66). WBMTB also correlated with urinary norepinephrine, epinephrine, dopamine and plasma dopamine, but not with serum chromogranin A. Tumour load per patient measured with (18)F-dopa PET correlates with tumour markers of the serotonin and catecholamine pathway in urine and plasma in carcinoid patients, reflecting metabolic tumour activity.
Keywords
Carcinoid tumour, (18)F-dopa PET, Whole-body metabolic tumour burden, 5-HIAA, POSITRON-EMISSION-TOMOGRAPHY, NEUROENDOCRINE TUMORS, CHROMOGRANIN-A, CARBIDOPA PRETREATMENT, CONSENSUS GUIDELINES, SOLID TUMORS, SEGMENTATION, EXTRACTION, SURVIVAL, CRITERIA

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 210.82 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Helle-Brit, Fiebrich, Johan R de Jong, Ido P Kema, Klaas Pieter Koopmans, Wim Sluiter, Rudi Dierckx, Annemiek M Walenkamp, Thera P Links, Adrienne H Brouwers, and Elisabeth GE de Vries. 2011. “Total 18F-dopa PET Tumour Uptake Reflects Metabolic Endocrine Tumour Activity in Patients with a Carcinoid Tumour.” European Journal of Nuclear Medicine and Molecular Imaging 38 (10): 1854–1861.
APA
Helle-Brit, F., de Jong, J. R., Kema, I. P., Koopmans, K. P., Sluiter, W., Dierckx, R., Walenkamp, A. M., et al. (2011). Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38(10), 1854–1861.
Vancouver
1.
Helle-Brit F, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx R, et al. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2011;38(10):1854–61.
MLA
Helle-Brit, Fiebrich, Johan R de Jong, Ido P Kema, et al. “Total 18F-dopa PET Tumour Uptake Reflects Metabolic Endocrine Tumour Activity in Patients with a Carcinoid Tumour.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 38.10 (2011): 1854–1861. Print.
@article{1922962,
  abstract     = {Positron emission tomography (PET) using 6-[(18)F]fluoro-L-dihydroxyphenylalanine ((18)F-dopa) has an excellent sensitivity to detect carcinoid tumour lesions. (18)F-dopa tumour uptake and the levels of biochemical tumour markers are mediated by tumour endocrine metabolic activity. We evaluated whether total (18)F-dopa tumour uptake on PET, defined as whole-body metabolic tumour burden (WBMTB), reflects tumour load per patient, as measured with tumour markers. 
Seventy-seven consecutive carcinoid patients who underwent an (18)F-dopa PET scan in two previously published studies were analysed. For all tumour lesions mean standardised uptake values (SUVs) at 40\% of the maximal SUV and tumour volume on (18)F-dopa PET were determined and multiplied to calculate a metabolic burden per lesion. WBMTB was the sum of the metabolic burden of all individual lesions per patient. The 24-h urinary serotonin, urine and plasma 5-hydroxindoleacetic acid (5-HIAA), catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A served as tumour markers. 
All but 1 were evaluable for WBMTB; 74 patients had metastatic disease. (18)F-dopa PET detected 979 lesions. SUV(max) on (18)F-dopa PET varied up to 29-fold between individual lesions within the same patients. WBMTB correlated with urinary serotonin (r = 0.51) and urinary and plasma 5-HIAA (r = 0.78 and 0.66). WBMTB also correlated with urinary norepinephrine, epinephrine, dopamine and plasma dopamine, but not with serum chromogranin A. 
Tumour load per patient measured with (18)F-dopa PET correlates with tumour markers of the serotonin and catecholamine pathway in urine and plasma in carcinoid patients, reflecting metabolic tumour activity.},
  author       = {Helle-Brit, Fiebrich and de Jong, Johan R and Kema, Ido P and Koopmans, Klaas Pieter and Sluiter, Wim and Dierckx, Rudi and Walenkamp, Annemiek M and Links, Thera P and Brouwers, Adrienne H and de Vries, Elisabeth GE},
  issn         = {1619-7070},
  journal      = {EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
  keyword      = {Carcinoid tumour,(18)F-dopa PET,Whole-body metabolic tumour burden,5-HIAA,POSITRON-EMISSION-TOMOGRAPHY,NEUROENDOCRINE TUMORS,CHROMOGRANIN-A,CARBIDOPA PRETREATMENT,CONSENSUS GUIDELINES,SOLID TUMORS,SEGMENTATION,EXTRACTION,SURVIVAL,CRITERIA},
  language     = {eng},
  number       = {10},
  pages        = {1854--1861},
  title        = {Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour},
  url          = {http://dx.doi.org/10.1007/s00259-011-1862-5},
  volume       = {38},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: